Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 316-323

  Abdelhamid, Emna ^a,b   Preudhomme, Claude ^b,c,d   Helevaut, Nathalie ^b,c   Nibourel, Olivier ^b,c,d   Gardin, Claude ^e   Rousselot, Philippe ^f   Castaigne, Sylvie ^f   Gruson, Bérengère ^g   Berthon, Céline ^b   Soua, Zohra ^a   Renneville, Aline ^b,c,d  

^a UNIVERSITY OF SOUSSE   (Tunisia)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Institut de Recherche sur le Cancer de Lille   (France)

^d UNIV LILLE   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; FLT3 internal tandem duplication; Minimal residual disease; Real time quantitative PCR

Indexed keywords

ANTHRACYCLINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLT3 GENE; GENE; GENE DUPLICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC MARKER; HUMAN; INTERNAL TANDEM DUPLICATION; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; NPM1 GENE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE; WT1 GENE;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEASIBILITY STUDIES; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TANDEM REPEAT SEQUENCES; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 84855967858     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.002     Document Type: Article

References (41)

1. Buccisano F., Maurillo L., Spagnoli A., Del Principe M.I., Fraboni D., Panetta P., et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010, 116:2295-2303.
2. Chou W.C., Hou H.A., Liu C.Y., Chen C.Y., Lin L.I., Huang Y.N., et al. Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. Annals of Oncology 2011, 22:696-704.
3. Kern W., Haferlach C., Haferlach T., Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 2008, 112:4-16.
4. Stirewalt D.L., Radich J.P. The role of FLT3 in the haematopoietic malignancies. Nature Reviews Cancer 2003, 3:650-665.
5. Renneville A., Roumier C., Biggio V., Nibourel O., Boissel N., Fenaux P., et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008, 22:915-931.
6. Meshinchi S., Appelbaum F.R. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clinical Cancer Research 2009, 15:4263-4269.
7. Peng H.L., Zhang G.S., Gong F.J., Shen J.K., Zhang Y., Xu Y.X., et al. Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia analysis of 147 patients. Croatian Medical Journal 2008, 5:650-659.
8. Boissel N., Cayuela J.M., Preudhomme C., Thomas X., Grardel N., Fund X., et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002, 16:1699-1704.
9. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100:59-66.
10. Levis M., Small D. FLT3: it does matter in leukemia. Leukemia 2003, 17:1738-1752.
11. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
12. Meshinchi S., Woods W.G., Stirewalt D.L., Sweetser D.A., Buckley J.D., Tjoa T.K., et al. Prevalence and prognostic significance of flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001, 97:89-94.
13. Breitenbuecher F., Schnittger S., Grundler R., Markova B., Carius B., Brecht A., et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2009, 113:4074-4077.
14. Callens C., Chevret S., Cayuela J.M., Cassinat B., Raffoux E., de Botton S., et al. Prognostic significance of FLT3 and Ras gene mutations in patients with acute promyeloytic leukemia (APL): a retrospective study from the European Group. Leukemia 2005, 19:1153-1160.
15. Gale R.E., Green C., Allen C., Mead A.J., Burnett A.K., Hills R.K., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784.
16. Stirewalt D.L., Kopecky K.J., Meshinchi S., Engel J.H., Pogosova-Agadjanyan E.L., Linsley J., et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 2006, 107:3724-3726.
17. Whitman S.P., Archer K.J., Feng L., Baldus C., Becknell B., Carlson B.D., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research 2001, 61:7233-7239.
18. Thiede C., Steudel C., Mohr B., Schaich M., Schäkel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
19. Schnittger S., Schoch C., Kern W., Hiddemann W., Haferlach T. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematologica 2004, 112:68-78.
20. Arber D.A., Brunning R.D., Le Beau M.M. Acute myeloid leukemia (AML) and related precursor neoplasms. WHO classification of tumors of haematpoietic and lymphoid tissues 2008, vol. 4:110-123. International Agency for Research on Cancer (IARC), Lyon, France.
21. ISCN: an international system for human cytogenetic nomenclature 1995, Karger, Basel. F. Mitelman (Ed.).
22. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial: the Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
23. Kiyoi H., Naoe T., Yokota S., Nakao M., Minami S., Kuriyama K., et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of Ministry of Health and Welfare (Kohseisho). Leukemia 1997, 11:1447-1452.
24. Boissel N., Renneville A., Biggio V., Philippe N., Thomas X., Cayuela J.M., et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005, 106:3618-3620.
25. Preudhomme C., Sagot C., Boissel N., Cayuela J.M., Tigaud I., de Botton S., et al. Favorable prognostic significance of CEBPα mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002, 100:2717-2723.
26. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Care R.S., Peake I.R., Reilly J.T. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukemia. British Journal of Haematology 2001, 113:983-988.
27. Gorello P., Cazzaniga G., Alberti F., Dell'Oro M.G., Gottardi E., Specchia G., et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006, 20:1103-1108.
28. Cilloni D., Renneville A., Hermitte F., Hills R.K., Daly S., Jovanovic J.V., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European Leukemia Net study. Journal of Clinical Oncology 2009, 27:5195-5201.
29. Small D. Targeting FLT3 for treatment of leukemia. Seminars in Hematology 2008, 45:1-8.
30. Weisberg E., Boulton C., Kelly L.M., Manley P., Fabbro D., Meyer T., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002, 1:433-443.
31. Stirewalt D.L., Willman C.L., Radich J.P. Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. Leukemia Research 2001, 25:1085-1088.
32. Beretta C., Gaipa G., Rossi V., Bernasconi S., Spinelli O., Dell'Oro M.G., et al. Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia. Leukemia 2004, 18:1441-1444.
33. Schnittger S., Kern W., Tschulik C., Weiss T., Dicker F., Falini B., et al. Minimal residual disease levels assessed by NPM1-specific RQ-PCR provide important prognostic information in AML. Blood 2009, 114:2220-2231.
34. Palmisano M., Grafone T., Ottaviani E., Testoni N., Baccarani M., Martinelli G. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. Heamatologica 2007, 92:1268-1269.
35. Kottaridis P.D., Gale R.E., Langabeer S.E., Frew M.E., Bowen D.T., Linch D.C. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002, 100:2393-2398.
36. Scholl S., Theuer C., Scheble V., Kunert C., Heller A., Mügge L.O., et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukemia. European Journal of Haematology 2008, 80:208-215.
37. Cilloni D., Gottardi E., De Micheli D., Serra A., Volpe G., Messa F., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2000, 16:2115-2121.
38. Candoni A., Tiribelli M., Toffoletti E., Cilloni D., Chiarvesio A., Michelutti A., et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. European Journal of Haematology 2008, 82:61-68.
39. Papadaki C., Dufour A., Seibl M., Schneider S., Bohlander S.K., Zellmeier E., et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. British Journal of Haematology 2008, 144:517-523.
40. Suzuki T., kiyoi H., Ozeki K., Tomita A., Yamaji S., Suzuki R., et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005, 106:2854-2861.
41. Barragan E., Pajuelo J.C., Ballester S., Fuster O., Cervera J., Moscardo F., et al. Minimal residual disease detection, in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression. Clinica Chimica Acta 2008, 395:120-123.